Featured Research

from universities, journals, and other organizations

Double duty for blood pressure drugs: How they could revolutionize how we treat valve disease

Date:
October 25, 2011
Source:
Heart and Stroke Foundation of Canada
Summary:
A type of medication known as angiotensin-receptor blockers could reduce risk of mortality in people with a heart disease called calcific aortic stenosis (AS) by 30 per cent over an eight-year period, according to experts. The condition is currently managed with open heart surgery.

A type of medication known as angiotensin-receptor blockers could reduce risk of mortality in people with a heart disease called calcific aortic stenosis (AS) by 30 per cent over an eight-year period, Heart and Stroke Foundation researcher Dr. Philippe Pibarot told delegates at the Canadian Cardiovascular Congress. The condition is currently managed with open heart surgery.

Related Articles


"Our discovery shifts how we think about AS by looking at a new pathway which both prevents and reverses calcification," says Dr. Pibarot, a professor at Laval University and Canada Research Chair in Valvular Heart Diseases, Québec Heart & Lung Institute. "It broadens how we can approach therapies, opening up new avenues of research, and has tremendous potential to lead to a major discovery."

From a health economics point of view, drug treatment is also far less expensive than replacing a valve through surgery, which Dr. Pibarot says costs at least $30,000.

Every year, AS is responsible for 10,000 to 15,000 deaths in North America, and upwards of 80,000 heart surgeries. Now, this promising research suggests the first possible drug therapy to treat AS.

"AS is one of the most common types of heart disease, yet the only option to save lives has been open heart surgery. And valve replacement surgery is the second most frequent heart surgery after coronary artery bypass," says Dr. Pibarot. "We may be able to slow the progress of AS to the point that most people won't need surgery."

Picture a normal heart valve as soft and thin, like a slice of tomato, Dr. Pibarot says. Compare that to a valve that has hardened and narrowed -- more like a cauliflower. That's calcific AS, the most common type of AS, where deposits of calcium form in the valve, which prevents it from opening properly and creates a dangerous 'pressure overload' within the heart.

For years, he notes, the assumption was that AS was a degenerative disease related to aging and the cumulative wear and tear on a heart valve. But more recent studies have indicated that AS development also has some genetic and lifestyle factors (such as obesity).

As a result, several trials have looked at whether statins (a class of drugs used to lower cholesterol levels) could also be effective against AS. Those results have not been promising. Dr. Pibarot and colleagues took another approach, examining medication that is typically used to treat high blood pressure (hypertension).

The renin-angiotensin system (RAS), specifically a molecule called angiotensin II, is a major target for drugs that lower blood pressure. Some hypertension drugs block the production of angiotensin II itself -- they are known as angiotensin-converting enzyme inhibitors (ACE inhibitors). Other drugs focus on the receptors of angiotensin II -- angiotensin-receptor blockers (ARBs).

Over three-and-a-half years, Dr. Pibarot's study followed 340 patients who had AS, 73 per cent of whom also had some degree of hypertension. Among the patients, 34 per cent were on ACE inhibitors, 16 per cent were on ARBs, and 50 per cent were on no RAS medication.

The follow-up involved measuring the velocity of the blood across the affected valve. As Dr. Pibarot explains, just as water flows faster when a river narrows, creating rapids, a narrowing valve raises pressure too. "A quicker blood velocity means the stenosis is progressing faster," he says.

Compared to the individuals who were on no medication, those who were on ACE inhibitors had less rapid narrowing of their valve. But the biggest difference was seen in patients on ARBs, where the receptors of angiotensin II are blocked. In those patients, the progress of the disease was slowed considerably -- three times slower than in the individuals who weren't taking any medication, reports Dr. Pibarot.

In effect, he says that with ARBs the current is slower, like on a calmer river.

In the absence of a drug treatment for AS, Dr. Pibarot's findings are potentially very significant, says Heart and Stroke Foundation spokesperson Dr. Beth Abramson.

"Open heart surgery can be effective, but is risky for many patients because of their age," says Dr. Abramson. "ARBs have the potential of slowing aortic stenosis significantly, so that we can prolong life without surgery."

She says that the need to find a medication solution is even more urgent when you consider that with the aging population the prevalence of valvular heart disease is expected to double within 15 years.

The Canadian Cardiovascular Congress 2011 is co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.


Story Source:

The above story is based on materials provided by Heart and Stroke Foundation of Canada. Note: Materials may be edited for content and length.


Cite This Page:

Heart and Stroke Foundation of Canada. "Double duty for blood pressure drugs: How they could revolutionize how we treat valve disease." ScienceDaily. ScienceDaily, 25 October 2011. <www.sciencedaily.com/releases/2011/10/111025091634.htm>.
Heart and Stroke Foundation of Canada. (2011, October 25). Double duty for blood pressure drugs: How they could revolutionize how we treat valve disease. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2011/10/111025091634.htm
Heart and Stroke Foundation of Canada. "Double duty for blood pressure drugs: How they could revolutionize how we treat valve disease." ScienceDaily. www.sciencedaily.com/releases/2011/10/111025091634.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Breakfast Debate: To Eat Or Not To Eat?

Breakfast Debate: To Eat Or Not To Eat?

Newsy (Oct. 23, 2014) — Conflicting studies published in the same week re-ignited the debate over whether we should be eating breakfast. Video provided by Newsy
Powered by NewsLook.com
Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) — Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Despite Rising Death Toll, Many Survive Ebola

Despite Rising Death Toll, Many Survive Ebola

AP (Oct. 23, 2014) — The family of a Dallas nurse infected with Ebola in the US says doctors can no longer detect the virus in her. Despite the mounting death toll in West Africa, there are survivors there too. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) — Is your child ready? Video provided by Working Mother
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins